Stamakort: A Literature Course on What Studies Report

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision related to peptides or supplements. It summarises what the published literature does and does not contain about a named product and its wider compound class, and it does not recommend any use.

Module 1: What Stamakort Is and How It Has Been Studied

Definition. Stamakort is a trade name used for an orally marketed preparation within the family of products generally described as "peptide bioregulators" — a catalogue of short peptide and peptide-fraction preparations developed and popularised largely by Russian gerontology groups from the 1990s onward. In that catalogue, individual product names are tied to an organ or tissue whose peptide fraction the preparation is said to correspond to; Stamakort is presented as the gastric or stomach-mucosa member of the series, alongside preparations aimed at other organ systems.

Class and origin

The scientific tradition behind these products rests on synthetic short peptides such as Vilon and Epitalon (also transliterated "epithalon" or "epitalon"), and on peptide preparations such as Pancragen, all of which appear in the peer-reviewed record. Researchers in that tradition studied enzyme activity in the intestinal epithelium of old rats after administration of vilon and epithalon in a Bulletin of Experimental Biology and Medicine report (PMID 12660839), and separately examined the functional morphology of radiosensitive organs after vilon and epithalon exposure using immunohistochemistry and morphometry (PMID 11427924). A later paper described prospects for using pancragen to correct metabolic disorders in elderly people (PMID 22448364). These are the compounds that the indexed literature actually names.

Forms

Products of this family are typically described as oral capsules containing peptide fractions with excipients, while the experimental peptides studied in the literature were administered in laboratory settings. A separate branch of the short-peptide literature concerns oral nutritional supplements built from short peptides rather than intact protein; two clinical cohorts used such supplements in patients after bariatric surgery (PMID 36501125, PMID 38530552).

Limits of the evidence for Module 1. None of the verified papers in this course studied, named or characterised a product called Stamakort. Everything below is class-adjacent literature on other short peptides and short-peptide supplements. Because product composition under a trade name is not established in the indexed record, no reader should assume that findings for Vilon, Epitalon, Pancragen or dietary short-peptide blends describe the same molecule or the same exposure.

Module 2: Mechanism as Described in the Literature

The mechanistic language used in this field is largely gene-expression regulation rather than receptor pharmacology. In a Lung paper, researchers examined peptide regulation of gene expression and protein synthesis in bronchial epithelium, framing short peptides as modulators of transcription and protein production in epithelial tissue (PMID 25015171). A related report described peptidergic regulation of the expression of genes encoding antioxidant and anti-inflammatory proteins (PMID 22803148). Taken together, these two papers define the mechanistic hypothesis of the class: that very short peptides interact with regulatory regions or signalling steps upstream of protein synthesis, rather than acting as classical hormones.

Gut-directed mechanisms

Because Stamakort is marketed with a gastrointestinal orientation, the most relevant mechanistic work concerns the gut. A 2025 Journal of Agricultural and Food Chemistry study combined transcriptomics with AlphaFold3 structural modelling and reported that novel short peptides enhanced the intestinal barrier and promoted nutrient absorption through the JAK-STAT pathway (PMID 40651001). Digestive-enzyme activity is a second mechanistic readout: the study of vilon and epithalon measured enzyme activity in epithelial and subepithelial layers of the small intestine in old rats (PMID 12660839), and a further report examined the effects of geroprotectors on age-related changes in proteolytic digestive enzyme activities under different lighting conditions (PMID 26519279).

Proliferation and apoptosis as mechanistic endpoints

Where short peptides are proposed to influence epithelial renewal, proliferation and apoptosis become the measured variables. Researchers assessed proliferative activity and apoptosis in colon tumours and colon mucosa in a rat carcinogenesis model involving epitalon (PMID 12964022), and morphometric and immunohistochemical methods were used to characterise radiosensitive organ morphology after vilon and epithalon administration (PMID 11427924).

Limits of the evidence for Module 2. These mechanisms were described for specific, chemically defined peptides in specific tissues — bronchial epithelium, intestinal epithelium, colon mucosa — and not for any commercial gastric preparation. Mechanistic plausibility is not evidence of a clinical effect. The JAK-STAT work was a laboratory and computational study (PMID 40651001), so pathway findings there cannot be read as human outcomes.

Module 3: Reported Outcomes by Study

The table below maps the verified literature by model, endpoint and what the authors reported at title and abstract level. No entry should be read as a benefit claim for any marketed product.

Limits of the evidence for Module 3. The animal studies used small, mechanistically focused designs with biochemical or histological endpoints, not symptom or disease outcomes. The two human datasets concerned nutritional short-peptide supplements in post-bariatric care, a context far from general gastric supplementation (PMID 36501125, PMID 38530552), and one of them was retrospective (PMID 38530552). No randomised placebo-controlled trial of a gastric peptide bioregulator product appears in this reference set. Doses are not stated anywhere on this page because the verified abstracts in scope do not supply dosing figures that could be reported accurately.

Module 4: Stamakort Side Effects: What Studies Report

The honest summary is that the verified literature contains no adverse-event profile for a product named Stamakort, and very little systematic safety reporting for the class. In the two human short-peptide supplement datasets, the reported endpoints were body-composition measures — early muscle mass after Roux-en-Y gastric bypass (PMID 36501125) and early fat-free mass loss after bariatric surgery (PMID 38530552) — rather than tolerability, discontinuation or laboratory-safety outcomes.

Safety-adjacent endpoints that were measured

• Tumour biology. Because peptides that influence epithelial turnover raise proliferation questions, researchers measured proliferative activity and apoptosis in colon tumours and mucosa in a rat carcinogenesis model with epitalon (PMID 12964022). That study is a safety-relevant design, but its findings apply to epitalon in rats, not to a marketed gastric capsule.
• Radiosensitive tissue morphology. Immunohistochemical and morphometric analysis of radiosensitive organs after vilon and epithalon administration provided histological rather than clinical safety data (PMID 11427924).
• Digestive enzyme shifts. Changes in intestinal enzyme activity were treated as outcomes of interest in old rats (PMID 12660839) and in geroprotector work on proteolytic digestive enzymes (PMID 26519279); such shifts are physiological findings, and the abstracts did not classify them as harms.

Limits of the evidence for Module 4. Absence of reported adverse events is not evidence of safety. None of the cited papers was designed or powered as a safety study of a commercial peptide bioregulator, no long-term human follow-up is present in this reference set, and the clinical gerontostomatology papers described practice and prospects rather than structured adverse-event collection (PMID 33775000, PMID 40570215).

Module 5: Pharmacokinetics Where Data Exist

For Stamakort specifically, no pharmacokinetic data exist in the verified literature: no absorption fraction, no plasma half-life, no distribution or elimination parameters, and no bioavailability comparison between routes. The class literature also does not close this gap. The gene-expression papers characterised transcriptional and protein-synthesis effects in tissue rather than plasma exposure (PMID 25015171, PMID 22803148), and the animal studies reported tissue-level biochemistry rather than concentration-time curves (PMID 12660839, PMID 26519279).

What can be said factually is that short peptides have been delivered enterally in humans in a nutritional context: the post-bariatric studies used oral short-peptide protein supplements and measured downstream body-composition endpoints (PMID 36501125, PMID 38530552). Separately, the barrier study reported that short peptides acted on intestinal barrier function and nutrient absorption through JAK-STAT signalling, which is a local gut-level mechanism rather than a systemic exposure measurement (PMID 40651001).

Limits of the evidence for Module 5. Oral administration in a nutrition trial does not establish that any particular peptide survives gastric and intestinal proteolysis intact, reaches systemic circulation, or produces measurable tissue concentrations. Without published pharmacokinetics, claims about "how long it stays active" or route equivalence have no support in this reference set.

Module 6: Regulatory Status, Stated Factually

Several separate facts matter here, and they are often blurred together in consumer-facing material.

1. Approved drug products. There is no United States Food and Drug Administration–approved drug product marketed under the name Stamakort, and the verified literature contains no regulatory approval documentation for it. The peptides most studied in this tradition — vilon, epithalon and pancragen — appear in the research record (PMID 11427924, PMID 22448364) without corresponding US drug approvals.
2. Research-use-only material. Substances in this space are frequently labelled "for research use only" or "not for human consumption." That label is a commercial and regulatory designation: it indicates the material has not been evaluated or authorised as a medicine and is not manufactured to pharmaceutical standards for human administration.
3. Dietary supplement framing. Peptide bioregulator capsules are commonly presented in some markets as supplements or parapharmaceuticals rather than as medicines. Supplement framing does not require demonstration of efficacy for a specific condition, which is one reason the peer-reviewed evidence base for trade-named products remains thin compared with the mechanistic literature on defined peptides (PMID 25015171).
4. Compounding. Under US law, a pharmacy or outsourcing facility compounding from a bulk drug substance generally needs that substance to be a component of an FDA-approved drug, the subject of an applicable USP or NF monograph, or listed on FDA's bulk drug substances list. Peptide preparations that meet none of those conditions fall outside the traditional compounding pathways.

The regulatory statements above are general information and not legal advice; rules differ by country and by state, and they change over time.

Limits of the evidence for Module 6. Regulatory status says nothing about biological activity, and research interest says nothing about legality or product quality. A compound can appear in dozens of papers and still have no approved product; conversely, a marketed capsule can carry a familiar trade name with no published trial behind it.

What the Studies Did Not Test

Closing this course means naming the gaps precisely:

• The product itself. No verified study tested a preparation named Stamakort, so no efficacy, dose, duration or safety statement about that product can be sourced from this literature.
• Human gastric endpoints. The verified human data concerned body composition after bariatric surgery (PMID 36501125, PMID 38530552) and clinical gerontostomatology practice (PMID 33775000, PMID 40570215), not endoscopic, histological or symptom outcomes in gastritis, ulcer disease or reflux.
• Translation from animal biochemistry. Enzyme-activity and morphometry findings in aged or irradiated rodents (PMID 12660839, PMID 11427924, PMID 26519279) were never followed by human confirmation in this reference set.
• Pathway specificity. The JAK-STAT barrier result applied to the specific novel peptides examined in that study (PMID 40651001), and the antioxidant and anti-inflammatory gene-expression work described a regulatory concept rather than a validated clinical mechanism (PMID 22803148).
• Oncologic safety in humans. Proliferation and apoptosis were measured in a rat colon model (PMID 12964022); no human oncologic safety data appear here.
• Pharmacokinetics, interactions and long-term use. None were characterised in the verified papers.

Readers evaluating any claim about this product can use a simple test drawn from the modules above: identify the compound actually studied, the species, the endpoint, and whether the paper reported an outcome or only proposed a mechanism. Again, this page is educational only and is not medical advice; questions about gastrointestinal symptoms or supplement use belong with a licensed physician.

References

• Peptide regulation of gene expression and protein synthesis in bronchial epithelium (Lung, 2014)
• Peptidergic regulation of expression of genes encoding antioxidant and anti-inflammatory proteins (Bulletin of Experimental Biology and Medicine, 2012)
• Effect of vilon and epithalon on activity of enzymes in epithelial and subepithelial layers in small intestine of old rats (Bulletin of Experimental Biology and Medicine, 2002)
• Immunohistochemical and morphometric analysis of effects of vilon and epithalon on functional morphology of radiosensitive organs (Bulletin of Experimental Biology and Medicine, 2001)
• Effects of Geroprotectors on Age-Related Changes in Proteolytic Digestive Enzyme Activities at Different Lighting Conditions (Bulletin of Experimental Biology and Medicine, 2015)
• Epitalon and colon carcinogenesis in rats: proliferative activity and apoptosis in colon tumors and mucosa (International Journal of Molecular Medicine, 2003)
• Novel Short Peptides Enhance the Intestinal Barrier to Promote Nutrient Absorption via the JAK-STAT Pathway Based on Transcriptomics and AlphaFold3 (Journal of Agricultural and Food Chemistry, 2025)
• Protein Supplementation with Short Peptides Prevents Early Muscle Mass Loss after Roux-en-Y-Gastric Bypass (Nutrients, 2022)
• Protein Supplements with Short Peptides Are Better than Complex Protein-Based Supplements on Improving Early Fat-Free Mass Loss Following Bariatric Surgery: A Retrospective Cohort Study (Obesity Surgery, 2024)
• Prospects of using pancragen for correction of metabolic disorders in elderly people (Bulletin of Experimental Biology and Medicine, 2011)
• Bioregulatory therapy in gerontostomatology: achievements and prospects (Advances in Gerontology, 2020)
• Peptide bioregulation in prosthetic stomatitis among the elder people (Advances in Gerontology, 2025)